All posts by medical

Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing – GlobeNewswire

TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they will provide COVID-19 testing to hundreds of thousands of students across approximately 1600 locations as they return to school in September and over the next several months. Fulgent will provide its FDA EUA-approved at-home test, Picture by Fulgent, a RT-PCR test that provides the highest level of sensitivity and specificity, utilizing a self-collected nasal swab sample. Fulgent will provide results within 24-48 hours from the time when Fulgent receives and accepts a specimen for the test.

Fulgent is very happy to partner with the City of New York on such an important and novel testing protocol. Its an ambitious goal to test so many students in such a rapid fashion, but the combination of the Fulgent technology platform and lab capacity along with the strong testing infrastructure of New York City makes this possible, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. In just a few short days, we were able to get the first shipment of hundreds of thousands of Picture kits to New York City. We will now be working closely with the city on the distribution, return and replenishment of the kits, added Perthuis.

This is one of the first large-scale testing programs for COVID-19 to utilize an at-home test kit. Fulgents Picture Genetics at-home test was chosen due to its convenient self-administration, which can be used on-site at schools as well as at home. The companys industry-leading turnaround time of 24-48 hours also makes this a powerful tool for back-to-school testing.

About NYC Test & Trace Corps

The NYC Test & Trace Corps is a public health initiative to fight COVID-19 so that New Yorkers can get back to school, work and help New York City reopen safely. The Corps is a group of doctors, public health professionals and community advocates working to reverse the COVID-19 outbreak and protect our city. The public health program is led by NYC Health + Hospitals in close collaboration with the NYC Department of Health and Mental Hygiene and other city agencies. Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. It ensures that anyone with the virus receives care and can safely isolate to prevent the spread. For more information, visit https://www.nychealthandhospitals.org/test-and-trace/.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.comfor more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; expected future lab capacity and turnaround times; expectations or guidance regarding future revenues and managements judgements and evaluations of the companys platform and technology.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Excerpt from:
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing - GlobeNewswire

Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years – Yahoo Finance

When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really flourishing, you can make more than 100%. Long term Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders would be well aware of this, since the stock is up 272% in five years. Then again, the 9.1% share price decline hasn't been so fun for shareholders.

See our latest analysis for Seattle Genetics

Given that Seattle Genetics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

For the last half decade, Seattle Genetics can boast revenue growth at a rate of 24% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 30% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes Seattle Genetics worth investigating - it may have its best days ahead.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth

Seattle Genetics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

We're pleased to report that Seattle Genetics shareholders have received a total shareholder return of 115% over one year. That's better than the annualised return of 30% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Seattle Genetics .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

See the original post:
Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years - Yahoo Finance

Merck Foundation and 13 African First Ladies meet to Strengthen Healthcare to control COVID 19 – Outlook India

(Eds: Disclaimer: The following press release comes to you under an arrangement with Business Wire India. PTI takes no editorial responsibility for the same.) Mumbai, Maharashtra, India & Cape Town, South Africa Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany conducted their first Video Conference Summit of Merck Foundation First Ladies Initiative (MFFLI) on 31st August 2020 to define and follow up on different joint programs that aims to advance public healthcare sector capacity and strengthen the response to COVID 19 in their countries. The MFFLI VC Summit 2020 was hosted by Prof. Dr. Frank Stangenberg Haverkamp, Chairman of the Executive Board of E. Merck KG and the Chairman of Merck Foundation Board of Trustees and Dr. Rasha Kelej, CEO of Merck Foundation and President, Merck More Than a Mother and One of 100 Most Influential African (2019 & 2020) and attended by 13 African First Ladies, who are Ambassadors of Merck More than a Mother; H.E. AUXILLIA MNANGAGWA, The First Lady of Zimbabwe; H.E. ESTHER LUNGU, The First Lady of Zambia; H.E. FATIMA MAADA BIO, The First Lady of Sierra Leone; H.E. ASSATA ISSOUFOU MAHAMADOU, The First Lady of Niger; H.E. MONICA GEINGOS, The First Lady of Namibia; H.E. ISAURA FERRO NYUSI, The First Lady of Mozambique; H.E. MONICA CHAKWERA, The First Lady of Malawi; H.E. REBECCA AKUFO-ADDO, The First Lady of Ghana; H. E. FATOUMATTA BAHBARROW, The First Lady of The Gambia; H.E. BRIGITTE TOUADERA, The First Lady of Central African Republic; H.E. ANGELINE NDAYISHIMIYE, The First Lady of Burundi; H.E. NEO JANE MASISI, The First Lady of Botswana; H.E. ANA DIAS LOURENO, The First Lady of Angola. Prof. Dr. Frank Stangenberg Haverkamp, Chairman of the Executive Board of E. Merck KG and the Chairman of Merck Foundation Board of Trustees emphasized, The effects of the COVID-19 pandemic have been greater than many expected across the globe. The pandemic has highlighted the importance of investing in improving access to equitable and quality healthcare which is Merck Foundation''s strategy since 2012, even before the pandemic started. Dr. Rasha Kelej, CEO of Merck Foundation explained, I am very proud of our valuable partnership with the African First ladies as Merck more than a Mother Ambassadors. We have always believed in the importance of building healthcare capacity through providing training to healthcare providers in many medical specialties. This has been our strategy since we started in 2012 in partnership with African First Ladies and Ministries of Health, much before the pandemic started. As a response to COVID 19 pandemic, we adopted online medical education strategy through providing more than 350 African doctors with one-year online diploma and two-year online master degree in many specialties such as: Respiratory Medicines and Acute medicines, Diabetes, Cardiology, Endocrinology, and Sexual and Reproductive Medicines. This is in addition to more than 500 African and Asian doctors who benefited from our original clinical training programs in Diabetes & Cardiovascular, Oncology, Fertility specialists, and embryology in India, Egypt, Kenya and Malaysia which will resume after the lockdown ends. The MFFLI VC Summit, special edition aims to share experiences, discuss challenges, and define solutions to further strengthen healthcare capacity to better respond to this global pandemic in Africa. The African First Ladies shared the experiences of working closely with Merck Foundation in their respective countries with special focus on the programs to build healthcare capacity and the response to COVID -19. H.E. AUXILLIA MNANGAGWA, The First Lady of Zimbabwe & Ambassador of Merck More Than a Mother emphasized, I am very happy to see Merck Foundations strong commitment to advance the public healthcare sector across Africa. This is very critical to Zimbabwe, in the light of current pressure on our healthcare sector. More than 117 local doctors are enrolled in these training programs which will transform our healthcare sector. H.E. ESTHER LUNGU, First Lady of Zambia & Ambassador of Merck More Than a Mother emphasized, We are proud of our partnership with Merck Foundation, which started in 2019. In a very short period, we have been able to reshape the healthcare landscape of Zambia by providing our doctors and nurses with specialty training in the fields of Cancer, Diabetes, Cardiology, Endocrinology, Respiratory, Acute medicines, Sexual and Reproductive medicines, Fertility and Embryology. All of these fields are very critical and were lacking in our country. This will contribute to our battle against coronavirus and other diseases. H.E. FATIMA MAADA BIO, The First Lady of Sierra Leone & Ambassador of Merck More Than a Mother expressed, I am extremely elated with our partnership with Merck Foundation, as together, we are making history in Sierra Leone by providing training for the First Oncologists in the country to establish the first skilled cancer care team. Also, our doctors are being trained in the fields of diabetes and fertility care. We will scale up the program to more fields together with Merck Foundation very soon. H.E. ASSATA ISSOUFOU MAHAMADOU, The First Lady of Niger & Ambassador of Merck More Than a Mother emphasized, I am happy to be part of this prestigious platform. Since the Merck Foundation launch in 2017, together we have made a significant impact on our healthcare sector, through establishing a strong platform of Health experts in very critical fields such as; Diabetes, Oncology and Fertility care in Niger. H.E. MONICA GEINGOS, The First Lady of Namibia & Ambassador of Merck More Than a Mother said, I am very happy to see that Merck Foundation is strongly committed to advancing the public healthcare sector across Africa. This is very critical to our countries in light of the current medical and public concerns. This is very important for Namibia as we have a very limited number of local specialists in the public sector, we are very happy to enroll 21 Namibian doctors in online diplomas in many fields, including 8 in sexual and reproductive medicines which is very important for women health. H.E. Dr. ISAURA FERRO NYUSI, The First Lady of Mozambique & Ambassador of Merck More Than a Mother explained, Together with Merck Foundation, I am fully committed to will work closely to introduce innovative ideas that will engage different sectors to create a culture shift with the aim to break the stigma of infertility and make a great impact in a short time. H.E. MONICA CHAKWERA, The First Lady of Malawi & Ambassador of Merck More Than a Mother said, I am looking forward to starting our important long term partnership with Merck Foundation. I am willing to capitalize on the valuable programs of Merck Foundation, by scaling them up nationwide to contribute to the social and economic development of Malawi. H.E. REBECCA AKUFO-ADDO, The First Lady of Ghana & Ambassador of Merck More Than a Mother elaborated, We launched the innovative programs of Merck Foundation at the beginning of 2019, to build healthcare capacity and break the infertility stigma. To share with you that since then and in a very short time we have been able to provide and enroll many of our healthcare providers with specialty training in the fields of Cancer, Diabetes, Cardiology, Endocrinology, Respiratory, Acute medicines, Sexual and Reproductive medicines, Fertility specialists and Embryology training. H.E. FATOUMATTA BAHBARROW, The First Lady of The Gambia & Ambassador of Merck More Than a Mother said, I am delighted to share the magnificent outcomes of my long term partnership with Merck Foundation. Together we have been able to empower infertile women through access to information, education, health, and change of mindset. Also, we have enrolled 25 Gambian doctors in One-year online diploma and one-year master degree in many medical specialties. H.E. BRIGITTE TOUADERA, The First Lady of Central African Republic & Ambassador of Merck More Than a Mother emphasized, I am very proud to work closely with Merck Foundation to advance healthcare sector and empower infertile women in my country. We also initiated in my country, an important project Empowering Berna where we established small businesses for infertile women and train them to run their businesses so they can have income and become independent. Their lives have been transformed since then. H.E. ANGELINE NDAYISHIMIYE, The First Lady of Burundi & Ambassador of Merck More Than a Mother expressed, I am very happy to be appointed the Ambassador of Merck More Than a Mother last week. I am excited about the work that has been done in my country so far and looking forward to taking this partnership to new heights. H.E. NEO JANE MASISI The First Lady of Botswana & Ambassador of Merck More Than a Mother highlighted, Merck Foundations strategy of building healthcare capacity is more relevant now than ever. More than 34 doctors were enrolled to different specialties, I will closely work with Merck Foundation and our Ministry of Health to ensure the success of this program to be able to improve our peoples health and wellbeing. H.E. ANA DIAS LOURENO, The First Lady of Angola expressed, I am very proud and happy to be a part of MFFLI VC Summit and look forward to a long-term partnership with Merck Foundation. We will closely work together on all their initiatives to build healthcare capacity and empower girls in education.About Merck Foundation First Ladies Initiative Summit MFFLIMFFLI is a Merck Foundation platform of African First Ladies and Merck More Than a Mother Ambassadors established with the aim to discuss challenges, define solutions, measure impact and share experience to ensure continuous improvement and exchange variable aspects of different cultures in order to localize and/or standardize specific messages that can raise awareness and create a culture shift across Africa with regards to the below objectives: Breaking the Stigma around infertile couples in general and infertile women in particular. Empowering Girls and Women in Education in general and in STEM in particular. Improving access to quality & equitable healthcare solutions.To View the Image Click on the Link Below:Merck Foundation First Ladies Initiative - VC Summit 2020 PWRPWR

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI

Read more from the original source:
Merck Foundation and 13 African First Ladies meet to Strengthen Healthcare to control COVID 19 - Outlook India

"We represent innovation and efficiency in the application of plant physiology" – hortidaily.com

Stoller Europe is the subsidiary of the American multinational Stoller Group, which serves the agricultural markets of Europe, North Africa, and Russia. "Our team is made up of highly qualified professionals who combine deep knowledge in plant physiology with an understanding of local crops and their specific problems," the company stated.

"Our approach to local farmers is based on transferring what happens to the crops to the field of scientific plant physiology, offering them comprehensive solutions to guarantee optimal production yields as well as the simple formation of complex physiological processes, thus ensuring a relationship of trust with the farmers that goes beyond purely commercial aspects."

"All of our product portfolio is based on this and there is a reason behind each measure in the field, a physiological explanation, a justification for each dose, and when it should be applied. Our products and close advisory work guarantee an environmentally and economically sustainable crop management that guarantees their quality. We at Stoller Europe believe that there are appropriate measures for appropriate times; as such, our main task is to understand the processes so that the handling of the products always yields maximum returns."

Stoller Europe's customer profile is very diverse: small, medium, and large producer. "Our clients aren't defined by their size or crop, but by their interest in improving their yields; their passion for continuous improvement and innovation. The company has grown and adapted to be able to closely serve customers with very different needs but under the same motivation. This premise was a fundamental pillar for Jerry Stoller, our founder."

"Year after year, we at Stoller strive to solve new challenges posed by growers, offering them new solutions and programs that are based on solid and innovative foundations of plant physiology. We constantly invest in research and development of new products and registrations. Our multinational nature allows us to have a complete global agricultural vision, a 360 vision of crops, which makes it easier to adapt global solutions to specific local problems. Stoller Group is interconnected and has multidisciplinary and global advisory teams, we share real experiences that keep us updated on trends and new agronomic challenges."

Stoller Europe's future challenges are to anticipate the needs of the increasingly dynamic and competitive agricultural sector, guaranteeing proximity to the farmer, through continuous training and profitable sustainable solution programs. "Our ultimate purpose is well defined in our motto 'Empowering Plants, Empowering People'."

For more information: Stoller Europe S.L.U.Elche Parque EmpresarialC/ Max Planck, 103203 Elche, Alicante (Espaa)Tel.: (+34) 965 110 522info@stollereurope.comhttps://stollereurope.com

Read more:
"We represent innovation and efficiency in the application of plant physiology" - hortidaily.com

Intuitive, integrated and efficient world premiere of Philips next-generation Azurion image-guided therapy platform – Yahoo Finance UK

Azurion image-guided therapy

Azurion image-guided therapy

Azurion IntraSight tableside monitor

Azurion SmartCT tableside monitor

September 1, 2020

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its next-generation Philips Azurion image-guided therapy platform, marking an important step forward in optimizing clinical and operational lab performance and expanding the role of image-guided interventions in the treatment of patients. Intuitive, integrated and efficient, the next-generation Azurion advances the capabilities of the platform to further improve the quality and efficiency of interventional procedures. The Azurion platform has already achieved rapid global adoption and has been used in well over two million procedures [1] worldwide since its introduction three years ago.

In the past few decades, clinical practices around the world have evolved to successfully treat more patients and perform more complex procedures in interventional labs. However, with more staff and technologies involved during these procedures, interventional lab environments can become crowded and cluttered. In order to enhance clinician focus and control during procedures, Philips has integrated all the essential lab systems and tools into this new version of the Azurion platform, making it an important step forward in lab integration.

Story continues

An industry-first, the Philips Azurion image-guided therapy platform now integrates control of imaging, physiology, hemodynamic and informatics applications, as well as intuitive control of the gantry, at the tableside, allowing clinicians to control all compatible applications from a single touch screen while performing procedures. This can eliminate the need for clinicians to leave the sterile field and step into an adjacent control room, as well as supporting faster and better informed decision making.

Simplifying 3D imaging during interventional proceduresWith this next-generation Azurion platform, Philips is also introducing a new 3D imaging solution called SmartCT [2]. With SmartCT, users are guided through the image acquisition and can review and interact with the acquired CT-like 3D images on the tableside touch screen module using 3D visualization and measurement tools. These tools have been designed to support procedures in a range of clinical domains, including neurology, oncology, and cardiovascular procedures. The use of 3D imaging such as 3D RA or Cone Beam CT during interventional procedures has been shown to improve outcomes [3] and reduce radiation dose for both staff and patients [4].

Our aim as an innovation company and global market leader in image-guided therapy is to push the boundaries and set new industry standards for delivering an outstanding experience for clinicians, helping them to deliver superior care to every patient, said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. This next-generation Azurion makes routine cardiovascular procedures more efficient and supports the development of new minimally-invasive techniques to treat complex diseases such as stroke, lung cancer and spine disorders.

"The integrated platform enables us to efficiently carry out complex interventions at any time using a wide range of functions such as IVUS and iFR co-registration, said Dr. med. Alexander Becker, head of the cardiac catheter laboratory at the Robert Bosch Hospital in Stuttgart, Germany, and one of the first hospitals to experience the new platform. The use of the control panel by the examiner is intuitive, combining different sources of information to make patient evaluation much easier and faster.

Seamless control and workflow during proceduresWith the new Azurion platform, clinicians can easily switch between imaging, physiology, hemodynamic and informatics applications, including SmartCT and IntraSight a comprehensive suite of clinically proven iFR, FFR, IVUS and co-registration modalities. Fully automatic position control enables clinicians to intuitively control the position of the gantry and table, as well as choosing from a wide range of stored parameters. The new Azurion also includes advanced cybersecurity features, new high-definition image display capabilities, and advanced remote and proactive services. The platform is available in three versions: complementing the Azurion 3 and 7 variants, Philips now also offers the Azurion 5 to facilitate even more tailored solutions to address specific customer needs. For more information visit http://www.philips.com/azurion.

[1] Based on Philips internal case and procedure data.[2] SmartCT is 510(k) pending and not available for sale in the USA.[3] Miyayama et al., Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma 6 cm with or without intraprocedural monitoring of the embolized area using cone beam computed tomography, CVIR 2014.[4] Schott et al., Radiation dose in prostatic artery embolization using Cone Beam CT and 3D roadmap software, JVIR 2019.

For further information, please contact:

Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email: mark.groves@philips.com

Twitter: mark_groves

Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622 698 001Email: fabienne.van.der.feer@philips.com

Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found atwww.philips.com/newscenter.

Attachments

Read more:
Intuitive, integrated and efficient world premiere of Philips next-generation Azurion image-guided therapy platform - Yahoo Finance UK

This 1988 Nobel Prize Winner is Responsible for Today’s Antiviral Treatments – Science Times

As coronavirus quickly spread throughout the world, infected millions, and continue to claim thousands of lives each day, medical experts across the globe began repurposing medication. By April, remdesivir, a drug that was used to treat Ebola, was used as antiviral treatment against the virus.

(Photo : Wikimedia Commons)

Antiviral drugs go back a few decades ago to a woman named Gertrude Elion, also known as Trudy, who was responsible for the reason scientists have developed so many antivirals today. Without her work, we may not have treatment for Ebola, HIV/AIDS, hepatitis, and many others.

In 1944, Elion was hired by George Hitchings, who owned the pharmaceutical company Burroughs Wellcome, which eventually became a part of GlaxoSmithKline. Twenty-three years later, after Hitchings retired from research, Elion went on an 'antiviral odyssey' on her own, which eventually led her to win the 1988 Nobel Prize in Physiology or Medicine.

She had come a long way as she struggled to get into a graduate program after studying chemistry at Hunter College due to financial hardships as a result of the Great Depression. At the time, most research laboratories would not hire women due to sexism and being told that she would only be 'a distracting influence' to male colleagues.

Elion persevered through temporary jobs to get through financially. She became a food analyst for a grocery company, worked at a doctor's office, and became a chemistry teacher in New York City high.

At the same time, she completed her master's degree at New York University. Before finally working at Burroughs Wellcome, she worked for Johnson & Johnson at the beginning of World War II since they were short on workers.

Before Elion's notable contributions to antiviral drugs, the first antibacterial treatment was penicillin. Alexander Fleminghad accidentally discovered the drug, which later on became a treatment for infections such as gonorrhea and pneumonia.

In 1952, surgeon and physiologist Henri Laboritbegan using chlorpromazine on patients. The anesthetic, he observed, had a calming effect from patients going through surgical shock during operations and helped those with schizophrenia.

During her time with Hitchings, Elion, and the rest of the company worked on proving the hypothesis that scientists could stop harmful cells from replicating after a viral infection. She was assigned to work on purines or chemical compounds, which she only understood after several months of research.

She soon made new compounds that no scientist could recognize. Marty. St. Clair, a virologist who worked for Elion years later, shared that "Trudy was making nucleosides before we even knew what the structure of DNA was."

READ: Remdesivir, a Direct-Acting Antiviral is Highly Potent in Inhibiting Coronavirus Replication, Study Says

Alongside Hitchings, they invented new drugs to treat conditions from bacterial infection, malaria, rheumatoid arthritis, leukemia, malfunctioning organs, and many other serious medical conditions. The first drug they developed was 6-mercaptopurine, which remains one of the treatments for acute lymphoblastic leukemia.

The last drug she developed was acyclovir, which inhibited herpes. Keith Jerome, from the University of Washington medical school, said, "Acyclovir was the drug that changed everything in the effort to develop effective antivirals."

Today, all antiviral treatment and developments have come from Trudy's work. With the current pandemic, medical experts believe that remdesivir could open the way to develop new drugs to treat coronavirus effectively.

READ NEXT: HIV and Antiviral Drugs Have Side-Effects on Coronavirus Patients and Do Not Cure Them, Scientists Say

Check out more news and information on Drug Treatmentson Science Times.

See the article here:
This 1988 Nobel Prize Winner is Responsible for Today's Antiviral Treatments - Science Times

Peloton Introduces Health And Wellness Advisory Council – SGB Media

Peloton announced the formation of a Health and Wellness Advisory Council working closely with the brand to support the physical and mental well being of its members.

Peloton will collaborate with the council, which includes five doctors, researchers and medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology, and neuroscience, and draw on their expertise to inform product and content development, community-focused and social impact initiatives, research projects and more.

We constantly hear from our members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression, said William Lynch, president, Peloton. With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform.

The Peloton Health and Wellness Advisory Council includes the following experts:

Suzanne Steinbaum, Cardiologist, specializing in prevention with a practice in New York City encompassing heart health, wellness and prevention as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a lifestyle management program using anatomy, physiology, functional data, genetics, and metabolism, along with technology to reach cardiovascular health. She has been the Director of Womens Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Womens Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Womens Heart Alliance.

Richard S. Isaacson, Neurologist, Clinician and Researcher specializin in Alzheimers prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimers disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimers disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimers Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimers disease, Journal of Communication in Healthcare, Alzheimers & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute inLos Angeles, CA.Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commissions Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty:Sports NeurologyandPain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for the optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Aimee M. Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center/New York-Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being the director of the adult pulmonary exercise laboratory for a decade. This cross-discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Laytons prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

Jay Alberts, Ph.D. is a research scientist aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinsons disease, stroke, Alzheimers, and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinsons disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer-reviewed articles, has had uninterrupted extramural funding since 1999, and holds 10 patents.

See original here:
Peloton Introduces Health And Wellness Advisory Council - SGB Media

Better way found to judge if certain drugs work to cure cancer : The Asahi Shimbun – Asahi Shimbun

Researchers in Tokyo came upwith a promising new way to gauge the effectiveness of certain drugs used to treat cancer.

Ateam led by Hiroyoshi Nishikawa, who heads the Division of Cancer Immunology at the National Cancer Center in the capital's Chuo Ward, developed an indicator that more precisely allows doctors to judge whether anti-cancer drugs like Opdivo that utilizes the immune system to fight cancer cells are working.

These medicines are not only very expensive, but can also cause debilitating side effects. Determining the effectiveness of treatment early on offers patients the opportunity to try other drugs if Opdivo turns out to be the wrong choice.

The immune system has T cells that attack cancer cells as well regulatory T cells that restrict such attacks. Drugs such as Opdivo weaken the ability of cancer cells to suppress the action of T cells. Thiseffectively allows the cells to more aggressively fight the cancer cells.

Tasuku Honjo, an immunologist at Kyoto University, shared the Nobel Prize in Physiology or Medicine in 2018 for his work in developing Opdivo.

A problem with drugs such as Opdivo is that they only work on about 20 to 30 percent of all cancer patients.

The team led by Nishikawa developed a way to preserve minute tissue samples in a fresh state and used the technique to look into the activity of molecules in cancer tissue taken from patients with lung and stomach cancer.

Using artificial intelligence, the team pinpointed the ideal combination of molecules on the surfaces of the cancer cell and various effector and regulatory T cells.

The researchers came up with an indicator to determine which patients would most likely benefit from cancer drugs, such as Opdivo, by searching for the proper balance in the molecules in the two types of T cells that restrain their attacks on cancer cells.

Samples from patients with the right ratio of molecules did not suffer a recurrence of the cancer cells even after 500 days. However, patients who did not have the right ratio experienced a relapse in about 100 days.

Nishikawa said his team would continue with the research to find an even more accurate method of determining which patients will benefit the most from certain drugs.

Indicators currently used on cancer cells only find that the drug is effective on about 40 percent of cancer patients, he said.

The results of the research were posted in the online version of the scientific journal Nature Immunology on Sept. 1.

The rest is here:
Better way found to judge if certain drugs work to cure cancer : The Asahi Shimbun - Asahi Shimbun

Kentucky by Heart: Many Kentuckians have made their mark in fields of science and technology – User-generated content

By Steve FlairtyNKyTribune Columnist

Science and technology. . .in the Bluegrass State??

Over the years, Kentucky hasnt always been given credit for its part in the furtherance of science and technology in the U.S., but after I did a little research this week, I discovered that the state has some real credibility in the area. There are a goodly number of people born in Kentucky who have been, or are, important participants in the fields as scientists or inventors.

Dr. Lee Todd (Photo from University of Kentucky)

For sure, my research is quite limited, especially regarding women excelling in this area. I would love to hear from my readers offering an expanded list.

Ive had the joyful experience to cross paths a few times with Dr. Lee Todd, Jr., former University of Kentucky president, born in the small town of Earlington, in Hopkins County. Hes a real gentleman, humble and a good listener, and hes a tireless promoter of sci/tech as a way to move the state forward economically and lift its peoples quality of life. Ill mention only a few of his accomplishments here.While a masters and doctoral student at Massachusetts Institute of Technology (MIT), he received six patents for high resolution display technology. Under his leadership as UK president, the university was awarded a 25-million-dollar grant from the National Science Foundation to improve math and science education in eastern Kentucky. Check out his initiatives; there are plenty more.

Dr. Phillip Sharp was born in Falmouth, the county seat of Pendleton County. Interestingly, he worked the family tobacco fields while growing up there. In 1993, he became the co-winner, with Richard Roberts, of the Nobel Prize in Physiology or Medicine in the field of RNA splicing. I previously profiled him in this KyForward column.

Isaac Chuang (Photo from MIT)

Awarded a degree in astronomy and astrophysics from Harvard, Louisville-born James Gilbert Baker (1914-2005) became a nationally known optical systems expert. He developed the Baker-Schmidt telescope and helped develop the Baker-Nunn camera, a series of twelve satellite tracking cameras. He also designed most of the lenses and cameras for Americas iconic U-2 spy plane.

Isaac Chuang is a native of Corbin and is recognized today as a pioneer in NMR quantum computing and has authored a primary reference book, along with Michael Neilsen, in the field of quantum information.

The president and chief executive officer of TWX Technologies, Rex Geveden, was born in western Kentucky, in Mayfield. Among many other high-profile positions, he formerly served as chief engineer at NASA.

Garrett A. Morgan (1877-1963), an African American, was born in Claysville, near Paris. His parents had been slaves. He became a well-known inventor, with his two most noted inventions being a three-position traffic signal and a smoke hood, which came before the gas mask. He pioneered some hair care products, too, and started a company with that line of products.

Garrett Morgon (Photo courtesy of Kentucky Monthly)

Besides Phillip Sharp, Kentucky had another winner of the Nobel Prize in Physiology or Medicine. Thomas Hunt Morgan (1866-1945), Lexington, won it in 1933 for his work in finding how the role that the chromosome plays in heredity. Interestingly, his first degree came in 1886 from the State College of Kentucky (later became UK), and he was valedictorian of the class. See https://www.bluegrasstrust.org/dr-thomas-hunt-morgan-house for a modern day tribute to Morgan.

A couple Kentuckians won the highest of rewards in the field of chemistry. William Lipscomb was born in Cleveland, Ohio, but his family moved to Lexington when he was a child. Lipscomb was the 1976 Nobel Prize in Chemistry recipient, specializing in nuclear magnetic resonance, theoretical chemistry, boron chemistry, and biochemistry. The other Kentuckian, Robert H. Grubbs, hails proudly from Marshall County (midway between Possum Trot and Calvert City.) His mother was a schoolteacher and his father a diesel mechanic. Grubbs was the co-recipient of the 2005 Nobel Prize in Chemistry for his work in olefin metathesis. Along with many other recognitions, in 2017 he was elected a Foreign Member of the Royal Society.

J. Richard Gott is a professor of astrophysical sciences and gravitational physics at Princeton University. Born in Louisville, he is known for his work in time travel and the Doomsday argument.

NASAs first Mars program director, G. Scott Hubbard, is a Lexington native. He received NASAs highest honor, the Distinguished Service Medal, and is the founder of the agencys Astrobiology Institute. Terrence W. Wilcutt, from Russellville and a Western Kentucky University graduate, is a U.S. Marine Corp officer and astronaut, a veteran of four Space Shuttle missions. He also has received a number of awards from NASA, including the Exceptional Service, Outstanding Leadership, and Distinguished Service medals.

The first industrial robot, named Unimate, was invented by George Devol (1912-2011), who was born in Louisville. He also created a company called United Cinephone and became known for his accomplishments as Grandfather of Robotics.

Though his accomplishments regarding the mobile radio transmitter-receiver were limited, Murray-born Nathan Stubblefield (1868-1928) proved a real player in inventing useful products. He patented a lamp lighter and electric battery, along with improvements in the invention of the telephone.

George M. Whitesides, another scientist from Louisville, is another nationally noted chemist. He is best known for his work in the areas of nuclear magnetic resonance spectroscopy, organometallic chemistry, molecular self-assembly, soft lithography, microfabrication, microfluidics, and nanotechnology. He attained the highest Hirsh index rating of all living chemists in 2011.

And whether one considers it for good or bad consequences, U.S. army officer John T. Thompson, from Newport, invented the Thompson submachine gun (often referred to as the Tommy Gun). I previously profiled him in this column Kentucky by Heart: Inventor of submachine gun was NKy native; finding strength in challenging times KyForward.com.

Science and technology in the Bluegrass?? Yep, we have game, and have for quite a few years.

Sources: Wikipedia; The Kentucky Encyclopedia

Read more here:
Kentucky by Heart: Many Kentuckians have made their mark in fields of science and technology - User-generated content

Peripheral Intravenous Education in North American Nursing Schools: A Call to Action – Healio

The majority (70% to 80%) of hospitalized patients require the placement of a vascular access device for intravenous therapy (Alexandrou et al., 2012; Zingg & Pittet, 2009). Peripheral intravenous (PIV) catheters allow venous system access for the infusion of fluids, medication, blood, or blood products (Hagle & Mikell, 2014). PIV catheter placement is one of the most frequent invasive skills performed by nurses working in hospitals (Ravik et al., 2017). Accurate placement and management of PIV catheters require significant knowledge, skill, and clinical judgement to reduce PIV-associated risks. If not managed correctly, PIV complications such as dislodgement, infection, phlebitis, occlusion, and/or infiltration/extravasation may occur (Infusion Nurses Society [INS], 2016; Weinstein & Hagle, 2014). Although theoretical and practical acquisition is a core component of nursing curricula, many nursing students and graduate nurses alike lack confidence in their PIV knowledge and skill (ECRI, 2019; Fink et al., 2008; Ravik et al., 2017; Wenger, 2015).

This descriptive, exploratory study examined PIV education delivery (i.e., content, time, and methodology [didactic, skills, simulation, clinical]) in U.S. and Canadian nursing programs. A team of researchers explored the current state of education provided to prelicensure nursing students, guided by the following research questions:

Delivery of quality, safe patient care is a cornerstone of nursing practice. Unfortunately, landmark studies, such as the Institute of Medicine's (2000) To Err Is Human: Building a Safer Health System, demonstrate that despite our best efforts health care is fraught with errors. In 2005, the Robert Wood Johnson Foundation funded a national study to prepare future nurses with the knowledge, skills, and attitudes to continuously improve the quality and safety of patient care (Quality and Safety Education for Nurses, 2019). ECRI, an organization dedicated to protecting patients from unsafe medical technologies and practices, released the Top 10 Patient Safety Concerns for 2019, which included #9: infections from peripherally inserted IV lines (ECRI, 2019, p. 12). ERCI (2019) noted, PIVs can expose patients to a significant risk of infectionone that is underreported, under recognized, and often ignored. Increased awareness of PIV catheter-related infections, coupled with routine active surveillance and follow-up reporting, can help reduce the risk (p. 12).

ECRI (2019) also identified the safety concern, developing and maintaining skills (#7), resulting from provider lack of confidence and competence performing procedures and/or using medical equipment (p. 10). Research links the lack of PIV education as one of the top reasons for PIV catheter complications and early catheter removal (Fakih et al., 2012; Keleekai et al., 2016; Unbeck et al., 2015). PIV complications can lead to increased length of stay (Helm et al., 2015), poor patient outcomes, and inflated patient costs (Helm et al., 2015; Keleekai et al., 2016; Taylor, 2015).

A study of U.S. and Canadian health care institutions found great variation in the PIV education and competency assessment of practicing nurses (Hunter et al., 2018). The majority of participating health care institutions felt nurses' PIV education was a shared responsibility between schools of nursing and health systems. Despite the fact that health care institutions expect graduate nurses to function at a novice level for PIV insertion, care, and maintenance, only four of 10 (43%) participating health systems included PIV education in their nursing orientation program and even fewer (18%) included it as part of the nurse residency program. Six percent of health systems indicated they did not provide any PIV education to their graduate nurses (Hunter et al., 2018). Finally, PIV competency assessment (i.e., psychomotor skill) was evaluated annually by fewer than two of 10 (16%) health care institutions or when a nurse transfers to select units (10%) (Hunter et al., 2018).

The insertion, care, and maintenance of PIV catheters requires application of complex knowledge and skills. Kavanagh and Szweda (2017) noted that:

knowledge development in clinical practice requires experiential teaching and learning through facilitated, situated cognition with reflection. Students, faculty, academic leaders, and service providers all share ownership in the success or failure of our new graduate nurses and their ability to develop a safe, effective practice.

When faculty teach students the skill of inserting a PIV catheter, they often do so using a linear approach (i.e., gather supplies, asses and prepare skin, insert catheter, connect fluid). Although this approach helps students to develop the psychomotor skill, it does not integrate the systematic approach needed to enhance clinical judgement as it pertains to PIV catheters. Knowledge and understanding of the complex PIV system, including anatomy (e.g., catheter-to-vessel ratio) and physiology (e.g., flow dynamics distal to central), combined with factors that contribute to PIV failure are critical to reducing PIV-associated risks.

The literature highlights concerns regarding the inconsistencies in PIV education and the limited opportunities for psychomotor PIV training for many new graduate nurses (Hunter et al., 2018). The INS 2013 IV Safety Practice Survey results found that more than half (57%) of the RN participants (n = 345) noted they were not taught how to perform the psychomotor skill of PIV placement in nursing school (Vizcarra et al., 2014). Seventy-one percent of these nurses reported receiving on the job training, whereas 11% reported they developed their PIV skills via the see-one, do-one, teach-one method. This limited PIV education likely contributes to reduced confidence in PIV skills. Studies found that graduate nurses identified PIV therapy as one of the top three skills they are least comfortable performing (Fink et al., 2008; Wenger, 2015). Lyons and Kasker (2012) further highlighted that even experienced nurses lacked confidence in their PIV catheter skills.

Furthermore, a lack of PIV education is one reason for PIV catheter complications and early PIV catheter removal (Fakih et al., 2012; Keleekai et al., 2016; Unbeck et al., 2015). Clay et al. (2017) demonstrated that less than 10% of medical and nursing students could identify a PIV catheter requiring replacement. PIV catheter insertion is a skill that graduate nurses are expected to grasp and comprehend, yet many are challenged to master this complex skill (Ravik et al., 2017). The current literature suggests that the delivery of a didactic PIV education program in combination with hands-on training results in significant improvements in PIV therapy outcomes (Alexandrou et al., 2012; Larsen et al., 2010; Lian et al., 2017; Lyons & Kasker, 2012; Vizcarra et al., 2014; Wilfong et al., 2011).

Lack of confidence and skill, as well as the pressure to initiate PIV access, can lead to unacceptable multiple PIV insertion attempts resulting in increased risk of patient harm. Data suggest that only 57% of patients experience a successful PIV catheter placement on the first attempt (iData, 2013), with most requiring at least two attempts (Hadaway, 2012). Multiple failed attempts result in vessel damage that limits future access and increases complication risk.

The acceptance of multiple attempts as the norm represents a type of normalization of deviance, a progressive acceptance by a group of people of small incremental changes that result in a lower level of safety (Odom-Forren, 2011, p. 216). Reasons for departure from standard practice may include lack of knowledge of the standards or seeing providers deviate from the standard of care (e.g., removing the finger of the glove during PIV insertion) (Odom-Forren, 2011). Eventually, deviations in practice are deemed acceptable and become the new normal. Use of an enhanced PIV curriculum by both nursing schools and professional development staff in health care institutions has potential to improve patient safety by reducing PIV complications and associated costs. This also has the potential to raise the confidence and skill level of nursing students and practicing nurses.

Nursing programs face many challenges in their curricular efforts to produce a nurse generalist who will have the requisite skills and knowledge upon graduation to successfully navigate the fast-paced world of patient care. Numerous sources of information guide the development of nursing curricula. These include accreditation standards (e.g., American Association of Colleges of Nursing (AACN) baccalaureate Essentials (2008), National League for Nursing (NLN) Commission for Nursing Education Accreditation (CNEA) Standards (2016), Accreditation Commission for Education in Nursing (ACEN) accreditation standards (2019), Canadian Association of Schools of Nursing (CASN) Standards (2014), and the National Council of State Boards of Nursing(NCSBN) NCLEX test plan (2019). To raise PIV knowledge, competence, and confidence of nursing students, it is expected that nursing curricula are grounded in professional standards. In the case of vascular access and infusion therapy, specialty organizations have published consensus statements, guidelines and standards including INS Infusion Therapy Standards of Practice (INS, 2016), Oncology Nursing Society (ONS) Access Device Standards (Camp-Sorrel & Matey, 2017), Canadian Vascular Access and Infusion Therapy Guidelines (Canadian Vascular Access Association [CVAA], 2019), and the Association for Vascular Access (AVA) Consensus Statements (Davis et al., 2016). These specialty organizations are dedicated to improving patient outcomes through promotion of vascular access and infusion therapy best practices. Professional organizations consider the quality and strength of the evidence in the development of practice guidelines and standards. Levels of evidence are assigned based on the study design, validity, and relevance to patient care. Many practice standards rely on key opinion leaders, clinical experts who serve as mediators in the development of these practice recommendations.

The NCSBN is responsible for the development and maintenance of the NCLEX-RN. The NCLEX test plan is based on the results of a national survey of a representative sample of 12,000 newly licensed RNs about the frequency and importance of performing nursing care activities (NCSBN, 2018). This test plan is revised every 3 years to measure the competencies needed to perform safely and effectively as a newly licensed, entry-level RN (NCSBN, 2019, p. 1). Survey results guide the development of the NCLEX test plan, including the distribution of content. Pharmacologic and parenteral therapies, including PIV therapy, comprised 12% to 18% of the items. Specifically, the nurse is expected to effectively monitor an intravenous infusion and maintain the PIV site. In addition, in the content area Reduction of Risk Potential, one of the activity statements is the insertion, maintenance, and removal of a PIV line (NCSBN, 2019).

Using a descriptive exploratory design, this study investigated how U.S. and Canadian colleges/schools of nursing educate students regarding PIV knowledge and skill. Participants were recruited to complete a 12-item questionnaire assessing the content, delivery method, clinical opportunities, and time dedicated to PIV education provided in the U.S. and Canadian colleges/schools of nursing. As an incentive, participants were offered the opportunity to enter a drawing for a $50 Amazon gift card by entering their contact information on a separate online site.

Researchers first obtained contact information for U.S. and Canadian nursing programs from the membership list for the AVA. To ensure a representative sample of both baccalaureate and associate degree programs, researchers also obtained nursing program information from the State Boards of Nursing in each of the 50 states. A Canadian nurse researcher obtained the contact information from Canadian programs. A web-based search of the nursing program websites provided the contact information for the nursing deans and directors or their representative. Finally, researchers reviewed the list of accredited programs from the AACN Commission on Collegiate Nursing Education, NLN CNEA, ACEN, and CASN. The result was a list of 633 U.S. (representing all 50 states) and 111 Canadian colleges/schools of nursing (representing all 10 provinces).

Following institutional review board approval, deans and administrators of U.S. and Canadian colleges/schools of nursing were sent an email inviting their school to participate in the electronic survey. To ensure accuracy of the responses, deans and directors were encouraged to forward the survey link to a faculty member most familiar with the PIV curriculum in their program. The recruitment email contained a link to a consent form that described the purpose and associated benefits and risks of participating. Consenting participants were taken to the 12-item online survey.

To encourage participation, researchers distributed a short video describing the study to the AVA electronic mailing list. AVA members were asked to reach out to the colleges/schools of nursing in their area. Finally, another member of the research team shared the opportunity to participate with attendees at the annual AVA meeting.

Representatives from 171 (27%) U.S. and Canadian nursing schools completed the PIV curriculum survey. Of the 171 participating schools, the majority (n = 112) represented baccalaureate degree (BSN) or equivalent programs (66%), 25 (15%) represented accelerated BSN programs, 29 (17%) represented 2-year associate degree (ADN) or equivalent programs (e.g., CEGEP Quebec), and five (3%) participants represented other types of nursing programs (e.g., diploma or Master of Science in Nursing Clinical Nurse Leader).

Participants were asked whether their curriculum included content on PIV and central vascular access. The majority of participating schools included PIV (87%) and central infusion therapy content (82%) at some point during the nursing program. Participants identified areas of PIV content and whether it was taught in the classroom (didactic), laboratory/simulation, or clinical settings. Areas receiving the most attention in the classroom included anatomy and physiology of the vascular system, types of parenteral solutions, patient education, and legal implications. Content taught more frequently in the laboratory/clinical setting included PIV catheter device types, catheter care, infection control, and venous visualization techniques. These topics were further reinforced in the clinical setting, particularly frequency of PIV monitoring, complications, and patient education. Table 1 demonstrates the PIV content covered and delivery method used (i.e., didactic/classroom, laboratory/simulation, clinical settings).

Table 1:

PIV Content Coverage and Delivery Modality in the Nursing Curriculum (N = 171)

When specifically asked about the use of case examples to demonstrate legal issues related to PIV placement, care, and documentation, the majority did not use such cases (65%). Most (73%) of the participants indicated that if they had access to a web-based, interactive PIV resource for student use, they would require students to complete the activities and use the time normally spent on PIV content to reinforce PIV concepts.

When asked about the courses in which PIV content was introduced and reinforced, most participants indicated it was introduced in the fundamentals and skills courses, with fewer participants introducing this content in medicalsurgical courses (Figure 1). Participants reinforce PIV content in pediatrics, medicalsurgical, obstetrics, and critical care and to a lesser extent in the leadership course.

Figure 1.

Courses in which peripheral intravenous education is taught and reinforced throughout the curriculum. Note. Med/Surg = medicalsurgical.

Participants were asked the amount of time dedicated to PIV content throughout the curriculum. Programs spent less than 1 to 2 hours of didactic class time (75%), with more instruction time (1 to 5 hours) dedicated to PIV in the laboratory/simulation setting (82%). Instruction was further reinforced in the clinical setting. In addition to classroom and laboratory/simulation, 90 (52%) of the participants indicated they incorporated a web-based, interactive PIV program.

Participants were then asked whether nursing students were able to start PIVs on patients in clinical settings. Ninety-one (61%) indicated nursing students in their program were able to initiate PIVs in the majority of clinical settings. Forty participants (27%) indicated students could initiate PIVs in some, but not all settings, and 18 (12%) indicated their students were unable to start PIVs in any clinical settings. The types of specialty units where students were least likely to initiate a PIV include pediatrics, community-based (e.g., home care), and psychiatric settings. Participants shared that individual health care institutional policies dictated students' ability to insert PIV catheters, rather than the nursing program. Even in schools where students were allowed to insert PIV catheters, most programs (72%) limited the number of attempts to two, which was the same limit for experienced nursing staff.

Participants indicated that nursing student PIV competence upon graduation was at the novice (56%) or advanced beginner level (35%). When asked about who has primary responsibility to educate nurses regarding PIV therapy, more than half of nursing program representatives (60%) thought it was a shared responsibility between the nursing school and health system/institution. Thirty-three percent thought it was the primary responsibility of the nursing school, and another 8% suggested it was the responsibility of the health system or institution.

The insertion of a PIV access device is one of the most common invasive procedures currently performed in health care, and it is perceived as a simple procedure (Vizcarra et al., 2014). Given the frequency of this invasive procedure and potential negative health outcomes when not appropriately managed, learning both the knowledge and skill associated with PIV is critical to patient safety.

Findings from this study demonstrate that PIV content coverage and practice opportunities comprise a small portion of the nursing didactic curriculum (1 to 2 hours) and laboratory/simulation instruction (1 to 5 hours). Simulation settings provide a safe environment in which to practice the skill of PIV insertion; however, students may find it difficult to transfer that knowledge to the clinical setting (Ravik et al., 2015). More concerning than time spent on PIV content are the limited opportunities to perform PIV catheter insertion in the clinical setting. Twelve percent of participating nursing programs indicated their nursing students were unable to initiate a PIV catheter during their clinical rotations. PIV knowledge and skill must be connected. When skills are learned only mechanically, the complexity of the knowledge behind the skill is not taken into consideration.

As noted previously, nursing knowledge development requires experiential teaching and learning through facilitated, situated cognition with reflection (Kavanagh & Szweda, 2017). Nurse educators are challenged to frame PIV content from both a knowing that and knowing how lens (Ravik, 2019). Knowing how to start a PIV focuses on the manual, psychomotor skill requiring manual dexterity and handeye coordination (Gomez & Gomez, 1987; Oermann, 1990). Knowing that involves a complex interplay between theoretical and practical knowledge, along with ethical and moral considerations (Benner, 1984; Ravik, 2019).

Changes to the NCLEX-RN examination include item types intended to measure clinical judgement more comprehensively; therefore, teaching clinical judgement related to PIV is important. NCLEX-RN plans to incorporate Next Generation NCLEX (NGN) item types such as hot spot (identify one or more areas on a picture or graphic) and exhibit, ordered response items (candidates rank order or move options), audio clips (using headphones), and graphic options (must select among a series of graphics instead of text), candidates may see items that evaluate their ability to assess and place PIV catheters (NCSBN, 2019). It is possible that candidates may see items that evaluate their ability to assess and place PIV catheters.

Perhaps nursing curricula should better emphasize advancing nursing students' knowledge of PIV care and maintenance early in the nursing curriculum to enhance clinical judgement. Once achieved, the focus can be shifted to PIV catheter insertion skills. However, a focus on care and maintenance may further limit clinical opportunities to practice PIV catheter insertion skills (Ravik et al., 2017). Although there is a growing body of literature regarding best practices for teaching PIV catheter insertion skills (Ravik, 2019; Ravik et al., 2015, 2017), gaps remain.

Adoption of reflection in parallel with skill performance may lead to enhanced learning. Ravik (2019) noted that intelligent practice involves intentional reflective practices to enable students to generate clear ideas of how to transfer the knowledge gained from the laboratory and simulation setting to the clinical area. Nurse educators are encouraged to facilitate intelligent practice in nursing students to ensure accurate skill performance, as well as the ability to adjust to individual patient needs. Likewise, health system nurse educators or individuals responsible for nurse residency programs are in a unique position to further develop graduate nurses' PIV knowledge and skill via ongoing professional education and competency assessment. The synergistic effect of the nursing curriculum, combined with the ongoing professional education, has the potential to improve not only the PIV confidence of graduate nurses but the skill as well.

Vascular access specialty organizations are an important source of evidence-based, best practices for both nurse educators and health care organizations alike. The AVA, CVAA, and INS provide web-based resources, including position papers, standards, and guidelinesmany of which are available at no cost. Nursing faculty are encouraged to join these professional organizations to stay current on the latest evidence-based practices. Nursing texts often reference standards of practice for infusion therapy including vascular access.

Strategies that nursing faculty could use to raise student awareness of PIV best practices is to invite a vascular access/IV team health care professional as a guest lecturer. These expert clinicians frequently are members of AVA, CVAA, and/or INS and are familiar with the vascular access/infusion therapy standards, guidelines, and position statements (Hunter et al., 2018). A second strategy faculty can use to enhance awareness of PIV and patient safety concerns is incorporation of legal case studies.

Faculty may enhance PIV learning opportunities by assigning students to clinical areas where PIV catheter insertion frequently occurs, such as outpatient surgery centers, emergency departments, and the radiology department. Another strategy would be to assign nursing students a day when they can work directly with a member of the vascular access team at the health system where clinical is completed. Such focused clinical experiences would expose them to clinical experiences often reserved only for expert PIV clinicians. Clinical objectives for this type of experience could include exposure to (a) best practices for infusion therapy, (b) patient safety (e.g., infection prevention) initiatives, (c) workflow management and triage, (d) device selection, (e) clinical decision making, (f) documentation, and (g) risk management considerations.

The organizations dedicated to vascular access and infusion therapy (e.g., AVA, CVAA, INS) recognize the need for improved PIV education and resources for health care providers (Table 2). In the past year, these organizations have launched educational portals for both members and non-members that provide continuing education modules to enhance nurses' knowledge of vascular access and infusion therapy ( https://www.avainfo.org/page/ava-academy; https://www.learningcenter.ins1.org/). The latest evidence on vascular access care and maintenance, legal/ethical concerns, infection control practices, and building vascular access competencies across the continuum are included. These provide access to the latest PIV evidence-based practice and other resources to support PIV knowledge foundation for proper skill development (AVA, 2019; INS, 2019). Unfortunately, some of these resources may be cost prohibitive to nonmembers and may be more appropriate for a more advanced provider. Ideally, vascular access and infusion therapy organizations would collaborate to assist prelicensure nursing programs to ensure an evidence-based curriculum to enhance PIV knowledge and skill acquisition. In fact, there are many recent innovative PIV simulation aides to improve PIV insertion skills that, the adoption of intelligent practice pedagogy, may also enhance overall PIV knowledge and skill.

Table 2:

Vascular Access Resources for Nurse Educators

Future studies are needed to determine the effectiveness of an enhanced PIV curriculum on improving the confidence, competence, and skill acquisition of nurses and other members of the health care team responsible for PIV insertion, care, and maintenance.

The majority of hospitalized patients experience PIV therapy at some point in their hospital stay and nurses are the most frequent provider to initiate PIV therapy. Research suggests that many nursing students and new graduate nurses feel less than confident in their PIV skills. Kavanagh et al. (2017) noted that faculty, students, academic leaders, and service providers all share ownership in the success or failure of graduate nurses' ability to develop safe, effective practice (p. 57). This is particularly relevant to PIV knowledge and skills. It is important for nursing students to understand the complexity of PIV content, including anatomy and physiology, pathophysiology, pharmacology, and assessment, before attempting to demonstrate PIV skill acquisition (Benner et al., 2010). Nursing students are eager to engage in hands-on nursing skills, especially the insertion of a PIV catheter. Unfortunately, emphasis on PIV skills undermines focus on learning the complexities of PIV care and maintenance and infusion therapy.

Nurse educators need to ensure that students are fully prepared to apply the knowledge learned when engaging in this complex skill. Strong academic practice partnerships are well suited to ensure a seamless transition for graduate nurses. Likewise, those responsible for nurse residency programs and continuing professional education/competency assessment must support new graduates whose PIV knowledge, skill, and confidence may be low. Including PIV content and skill development in such programs is important for patient safety and positive patient outcomes. For a task that remains ubiquitous to patient care while carrying a high volume, high-risk designation, PIV education should be enhanced in prelicensure curricula. Vascular access and infusion specialty organizations provide resources to advance both generalist nursing knowledge and the knowledge of practicing health care professionals. Use of these resources along with advanced PIV simulation aids can support student learning and may lead to increased confidence of graduate nurses.

Although the sampling method for this study included both prelicensure associate and baccalaureate degree programs from the United States and Canada, there is no way to determine the geographic representation of the sample. Likewise, use of a convenience sample limits the generalizability of the findings. Finally, lack of published, evidence-based PIV student standards and guidelines makes consistent application of teaching learning methods regarding PIV difficult.

PIV Content Coverage and Delivery Modality in the Nursing Curriculum (N = 171)a

Vascular Access Resources for Nurse Educators

More here:
Peripheral Intravenous Education in North American Nursing Schools: A Call to Action - Healio